​

Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?


OverviewForecastFinancialsChart

Enliven Therapeutics Ownership Summary


Enliven Therapeutics is owned by 128.23% institutional investors, 6.23% insiders. Fmr is the largest institutional shareholder, holding 16.36% of ELVN shares. Polar Capital Healthcare Opports Inc is the top mutual fund, with 4.93% of its assets in Enliven Therapeutics shares.

ELVN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEnliven Therapeutics128.23%6.23%-34.46%
SectorHealthcare Stocks 247.07%12.15%-159.22%
IndustryBiotech Stocks 385.89%11.79%-297.68%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr10.83M16.36%$496.34M
Orbimed advisors6.78M10.79%$343.91M
Polar capital6.43M10.24%$326.35M
Blackrock funding, inc. /de5.71M8.63%$261.84M
Vestal point capital, lp4.00M6.37%$203.00M
Commodore capital lp3.27M5.21%$166.21M
Price t rowe associates inc /md/2.90M4.62%$147.37M
Vanguard group2.80M4.51%$43.15M
Vanguard capital management2.89M4.37%$132.62M
Citadel advisors2.07M3.29%$105.00M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Commodore capital lp3.27M9.90%$166.21M
Orbimed advisors6.78M6.41%$343.91M
Fairmount funds management1.86M6.22%$94.17M
Tri locum partners lp866.72K5.41%$43.99M
First turn management954.36K5.18%$48.43M
Vestal point capital, lp4.00M4.74%$203.00M
Avidity partners management lp550.00K4.47%$27.91M
First light asset management1.36M4.20%$69.06M
Exome asset management100.20K3.14%$5.09M
Stempoint capital lp346.91K3.03%$17.61M

Top Buyers

HolderShares% AssetsChange
Price t rowe associates inc /md/2.90M0.01%2.81M
Polar capital6.43M0.77%1.36M
Blackrock funding, inc. /de5.71M0.00%1.35M
First light asset management1.36M4.20%1.16M
Adage capital partners gp1.08M0.08%1.08M

Top Sellers

HolderShares% AssetsChange
Janus henderson group11.00K0.00%-1.66M
Point72 asset management---1.50M
Capital research global investors---1.30M
Vr adviser526.33K0.81%-1.20M
Orbimed advisors6.78M6.41%-1.18M

New Positions

HolderShares% AssetsChangeValue
Adage capital partners gp1.08M0.08%1.08M$54.98M
Samlyn capital912.64K0.75%912.64K$46.32M
Tri locum partners lp866.72K5.41%866.72K$43.99M
Westfield capital management co lp766.55K0.12%766.55K$35.14M
Principal financial group332.24K0.01%332.24K$15.23M

Sold Out

HolderChange
National bank of canada /fi/-7.00
Mai capital management-7.00
Covestor-15.00
Td capital management-16.00
Stephens consulting-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202621821.11%80,527,06629.07%1281.06%15318.60%4845.45%
Mar 31, 202690-29.13%11,947,495-80.85%210.21%64-1.54%17-62.22%
Dec 31, 202585-36.09%19,456,209-67.24%310.34%42-46.84%3413.33%
Sep 30, 202552-57.72%9,174,149-84.56%170.14%34-58.02%10-56.52%
Jun 30, 20251220.83%59,425,06519.12%1141.14%8023.08%23-30.30%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Polar Capital Healthcare Opports Inc3.61M4.93%-
Polar Capital Biotech S Inc2.56M3.49%-
Vanguard MStar Total Stk Mkt Idx Invest2.11M2.87%218.04K
Vanguard Morn Total Stk Mkt Idx Investor1.88M2.64%276.54K
Vanguard Total Stock Mkt Idx Inv1.88M2.64%276.54K
Fidelity Small Cap Growth1.52M2.06%-
iShares Russell 2000 ETF1.48M2.01%-
Fidelity Select Health Care1.28M1.75%-60.00K
Strategic Advisers Fidelity US TtlStk1.12M1.53%385.67K
Pictet-Biotech P USD865.27K1.18%98.59K

Recent Insider Transactions


DateNameRoleActivityValue
Oct 19, 2026Hohl Benjamin CHIEF FINANCIAL OFFICERSell$231.55K
Oct 19, 2026Collins Helen Louise CHIEF MEDICAL OFFICERSell$192.34K
Oct 01, 2026Garland J. Scott-Sell$606.72K
Sep 17, 2026Hohl Benjamin CHIEF FINANCIAL OFFICERSell$111.27K
Sep 17, 2026Hohl Benjamin CHIEF FINANCIAL OFFICERSell$14.88K

Insider Transactions Trends


DateBuySell
2026 Q4-3
2026 Q3-23
2026 Q2-21
2026 Q1-21
2025 Q4-11

ELVN Ownership FAQ


Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 128.23%, followed by 6.23% insiders and -34.46% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 385.89%, which Enliven Therapeutics falls below.

Who owns the most shares of Enliven Therapeutics?

Enliven Therapeutics’s largest shareholders are Fmr (10.83M shares, 16.36%), Orbimed advisors (6.78M shares, 10.79%), and Polar capital (6.43M shares, 10.24%). Together, they hold 37.39% of Enliven Therapeutics’s total shares outstanding.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Commodore capital lp is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.90% of its assets in 3.28M Enliven Therapeutics shares, valued at 166.21M$.

Who is the top mutual fund holder of Enliven Therapeutics shares?

Polar Capital Healthcare Opports Inc is the top mutual fund holder of Enliven Therapeutics shares, with 4.93% of its total shares outstanding invested in 3.61M Enliven Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools